JP2015519356A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519356A5 JP2015519356A5 JP2015514503A JP2015514503A JP2015519356A5 JP 2015519356 A5 JP2015519356 A5 JP 2015519356A5 JP 2015514503 A JP2015514503 A JP 2015514503A JP 2015514503 A JP2015514503 A JP 2015514503A JP 2015519356 A5 JP2015519356 A5 JP 2015519356A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- dose
- inhalation
- dry powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- SFYAXIFVXBKRPK-QFIPXVFZSA-N abediterol Chemical compound C([C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)NCCCCCCOCC(F)(F)C1=CC=CC=C1 SFYAXIFVXBKRPK-QFIPXVFZSA-N 0.000 claims 12
- 229950000192 abediterol Drugs 0.000 claims 12
- 239000012458 free base Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000843 powder Substances 0.000 claims 9
- 239000003937 drug carrier Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 5
- 229960002744 mometasone furoate Drugs 0.000 claims 5
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical group O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
- XLAKJQPTOJHYDR-QTQXQZBYSA-M aclidinium bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 XLAKJQPTOJHYDR-QTQXQZBYSA-M 0.000 claims 2
- 239000010419 fine particle Substances 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229960002714 fluticasone Drugs 0.000 claims 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims 1
- 229960002586 roflumilast Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical group O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12382221.5A EP2668941A1 (en) | 2012-05-31 | 2012-05-31 | Novel dosage form and formulation of abediterol |
| EP12382221.5 | 2012-05-31 | ||
| US201261660003P | 2012-06-15 | 2012-06-15 | |
| US61/660,003 | 2012-06-15 | ||
| PCT/EP2013/061181 WO2013178742A1 (en) | 2012-05-31 | 2013-05-30 | Novel dosage form and formulation of abediterol |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015519356A JP2015519356A (ja) | 2015-07-09 |
| JP2015519356A5 true JP2015519356A5 (enExample) | 2016-06-16 |
| JP6272836B2 JP6272836B2 (ja) | 2018-01-31 |
Family
ID=46317311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514503A Expired - Fee Related JP6272836B2 (ja) | 2012-05-31 | 2013-05-30 | アベジテロールの新規の剤形および製剤 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US20150140099A1 (enExample) |
| EP (2) | EP2668941A1 (enExample) |
| JP (1) | JP6272836B2 (enExample) |
| KR (2) | KR20150018526A (enExample) |
| CN (1) | CN104394852A (enExample) |
| AR (1) | AR091233A1 (enExample) |
| AU (1) | AU2013269565B2 (enExample) |
| BR (1) | BR112014029735A2 (enExample) |
| CA (1) | CA2871358C (enExample) |
| CL (1) | CL2014003286A1 (enExample) |
| CO (1) | CO7141434A2 (enExample) |
| CR (1) | CR20140540A (enExample) |
| DO (1) | DOP2014000271A (enExample) |
| EA (1) | EA201401354A1 (enExample) |
| EC (1) | ECSP14028814A (enExample) |
| HK (1) | HK1203149A1 (enExample) |
| IL (1) | IL235831B (enExample) |
| IN (1) | IN2014DN08672A (enExample) |
| MX (1) | MX2014014350A (enExample) |
| MY (1) | MY184654A (enExample) |
| NI (1) | NI201400139A (enExample) |
| NZ (1) | NZ701261A (enExample) |
| PE (1) | PE20150171A1 (enExample) |
| PH (1) | PH12014502662A1 (enExample) |
| SG (3) | SG10201913424SA (enExample) |
| TW (1) | TWI610690B (enExample) |
| UY (1) | UY34838A (enExample) |
| WO (1) | WO2013178742A1 (enExample) |
| ZA (1) | ZA201407405B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| WO2014007781A2 (en) * | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions |
| AU2015275933A1 (en) * | 2014-06-18 | 2017-02-02 | Cipla Limited | Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent |
| WO2019142214A1 (en) * | 2018-01-19 | 2019-07-25 | Cipla Limited | Pharmaceutical composition comprising tiotropium for inhalation |
| JP2021524323A (ja) | 2018-05-22 | 2021-09-13 | シー・アール・バード・インコーポレーテッドＣ Ｒ Ｂａｒｄ Ｉｎｃｏｒｐｏｒａｔｅｄ | カテーテル挿入システム及びその使用方法 |
| JP7314252B2 (ja) | 2018-08-10 | 2023-07-25 | シー・アール・バード・インコーポレーテッド | 自動尿量測定システム |
| US12083261B2 (en) | 2020-06-05 | 2024-09-10 | C. R. Bard, Inc. | Automated fluid output monitoring |
| US12055249B2 (en) | 2020-07-21 | 2024-08-06 | C. R. Bard, Inc. | Automatic fluid flow system with retractable connection |
| US12408853B2 (en) | 2020-12-17 | 2025-09-09 | C. R. Bard, Inc. | Smart bag to measure urine output via catheter |
| US12364423B2 (en) | 2020-12-21 | 2025-07-22 | C. R. Bard, Inc. | Automated urinary output-measuring systems and methods |
| US11931151B2 (en) | 2020-12-22 | 2024-03-19 | C. R. Bard, Inc. | Automated urinary output measuring system |
| US12246146B2 (en) | 2020-12-23 | 2025-03-11 | C. R. Bard, Inc. | Automated weight based fluid output monitoring system |
| US12446813B2 (en) | 2021-08-23 | 2025-10-21 | C. R. Bard, Inc. | Automated urine output system for attachment to hospital bed |
| WO2025151671A1 (en) * | 2024-01-12 | 2025-07-17 | Texas Tech University System | Compositions and methods for treating diet-induced obesity and associated metabolic disorders |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT7920688U1 (it) | 1979-02-05 | 1980-08-05 | Chiesi Paolo | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore |
| EP0069715B1 (en) | 1981-07-08 | 1986-11-05 | Aktiebolaget Draco | Powder inhalator |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| FI69963C (fi) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | Doseringsanordning |
| DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
| IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
| WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
| DE4027391A1 (de) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
| ATE209938T1 (de) | 1990-09-26 | 2001-12-15 | Pharmachemie Bv | Wirbelkammer-pulverinhalator |
| GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| DE4239402A1 (de) | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
| DE69323897T2 (de) | 1992-12-18 | 1999-11-04 | Schering Corp., Kenilworth | Inhalator für pulverförmige medikamente |
| CZ294700B6 (cs) | 1995-06-21 | 2005-02-16 | Sofotec Gmbh & Co. Kg | Pouzdro na farmaceutický prášek pro práškové inhalátory |
| DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
| ITMI20010357U1 (it) | 2001-06-28 | 2002-12-30 | Plastiape Spa | Dispositivo inalatore |
| ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| CA2540005A1 (en) * | 2003-09-26 | 2005-04-07 | Schering Corporation | Pulmonary disease treatment |
| ES2232306B1 (es) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2251867B1 (es) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| MX2007000592A (es) | 2004-07-16 | 2008-03-04 | Almirall Lab | Inhalador para la administracion de farmaceuticos en polvo, y un sistema de cartuchos de polvo para uso con este inhalador. |
| ES2265276B1 (es) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico. |
| ES2306595B1 (es) | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2. |
| EP2100598A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
| EP2221055A1 (en) * | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function |
| EP2221297A1 (en) * | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases |
-
2012
- 2012-05-31 EP EP12382221.5A patent/EP2668941A1/en not_active Withdrawn
-
2013
- 2013-05-30 US US14/404,199 patent/US20150140099A1/en not_active Abandoned
- 2013-05-30 CN CN201380028903.4A patent/CN104394852A/zh active Pending
- 2013-05-30 HK HK15103713.3A patent/HK1203149A1/xx unknown
- 2013-05-30 PE PE2014002064A patent/PE20150171A1/es not_active Application Discontinuation
- 2013-05-30 KR KR1020147033563A patent/KR20150018526A/ko not_active Ceased
- 2013-05-30 JP JP2015514503A patent/JP6272836B2/ja not_active Expired - Fee Related
- 2013-05-30 CA CA2871358A patent/CA2871358C/en active Active
- 2013-05-30 NZ NZ701261A patent/NZ701261A/en not_active IP Right Cessation
- 2013-05-30 EA EA201401354A patent/EA201401354A1/ru unknown
- 2013-05-30 SG SG10201913424SA patent/SG10201913424SA/en unknown
- 2013-05-30 TW TW102119230A patent/TWI610690B/zh not_active IP Right Cessation
- 2013-05-30 WO PCT/EP2013/061181 patent/WO2013178742A1/en not_active Ceased
- 2013-05-30 EP EP13728344.6A patent/EP2854771A1/en not_active Withdrawn
- 2013-05-30 BR BR112014029735A patent/BR112014029735A2/pt not_active Application Discontinuation
- 2013-05-30 SG SG10201609119VA patent/SG10201609119VA/en unknown
- 2013-05-30 IN IN8672DEN2014 patent/IN2014DN08672A/en unknown
- 2013-05-30 MY MYPI2014703543A patent/MY184654A/en unknown
- 2013-05-30 KR KR1020187026487A patent/KR20180104197A/ko not_active Ceased
- 2013-05-30 AU AU2013269565A patent/AU2013269565B2/en not_active Ceased
- 2013-05-30 MX MX2014014350A patent/MX2014014350A/es unknown
- 2013-05-30 SG SG11201407110QA patent/SG11201407110QA/en unknown
- 2013-05-31 UY UY0001034838A patent/UY34838A/es not_active Application Discontinuation
- 2013-05-31 AR ARP130101927 patent/AR091233A1/es unknown
-
2014
- 2014-10-13 ZA ZA2014/07405A patent/ZA201407405B/en unknown
- 2014-11-20 IL IL235831A patent/IL235831B/en active IP Right Grant
- 2014-11-25 NI NI201400139A patent/NI201400139A/es unknown
- 2014-11-26 CR CR20140540A patent/CR20140540A/es unknown
- 2014-11-26 EC ECIEPI201428814A patent/ECSP14028814A/es unknown
- 2014-11-26 DO DO2014000271A patent/DOP2014000271A/es unknown
- 2014-11-27 CO CO14260864A patent/CO7141434A2/es unknown
- 2014-11-28 PH PH12014502662A patent/PH12014502662A1/en unknown
- 2014-11-28 CL CL2014003286A patent/CL2014003286A1/es unknown
-
2016
- 2016-06-30 US US15/198,289 patent/US20160303108A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519356A5 (enExample) | ||
| RU2010141331A (ru) | Новая доза и препаративная форма | |
| RU2010141333A (ru) | Новая доза и препаративная форма | |
| RU2013142268A (ru) | Фармацевтическая композиция | |
| JP2012082229A (ja) | 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法 | |
| HK1203149A1 (en) | Novel dosage form and formulation of abediterol | |
| CA2749231A1 (en) | Pharmaceutical composition for inhalation | |
| JP2013542940A5 (enExample) | ||
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| FI3500241T3 (fi) | Yhdistelmähoito copd:lle | |
| JP2018537453A5 (enExample) | ||
| JP2013507429A5 (enExample) | ||
| AU2015261103A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of COPD | |
| US20120101077A1 (en) | Agglomerate formulations useful in dry powder inhalers | |
| KR20140007929A (ko) | 호흡기 환자의 수면의 질을 개선하는데 사용되는 아클리디늄 | |
| CN107496388B (zh) | 一种含有福莫特罗和噻托铵盐组合物的粉状制剂及其制备方法 | |
| EP2682099B1 (en) | Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists | |
| JP2011500731A5 (enExample) | ||
| MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
| JP2016502992A5 (enExample) | ||
| JP2013522295A5 (enExample) | ||
| TW201605440A (zh) | 阿地銨之新用途 |